We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Oncotelic Therapeutics, Inc. (OTLC) are developing three lines of therapeutics. 1) Oncology/Virology - we are developing OT-101 (TGF-beta antisense/ Artemisinin) and VDA agents (Oxi4503/CA4P) against viral infections and various tumors including three rare pediatric tumors (DIPG, Melanoma, and AML).... Oncotelic Therapeutics, Inc. (OTLC) are developing three lines of therapeutics. 1) Oncology/Virology - we are developing OT-101 (TGF-beta antisense/ Artemisinin) and VDA agents (Oxi4503/CA4P) against viral infections and various tumors including three rare pediatric tumors (DIPG, Melanoma, and AML). The program is being funded by our partner GMP through a JV that we are intend to take IPO. 2) AL-101 (intranasal-apomorphine) for the treatment of Parkinson Disease, Erectile Dysfunction not responding to PDE5 inhibitor, and Female Sexual Dysfunction. 3) Animal health product including oncology (CA4P and Artemishas). Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0038 | 13.1034482759 | 0.029 | 0.0364 | 0.029 | 203981 | 0.03560773 | CS |
4 | -0.0022 | -6.28571428571 | 0.035 | 0.036795 | 0.025 | 159139 | 0.03122882 | CS |
12 | 0.013705 | 71.7727153705 | 0.019095 | 0.04 | 0.019095 | 262882 | 0.0307112 | CS |
26 | 0.0018 | 5.8064516129 | 0.031 | 0.04 | 0.017 | 251817 | 0.02652673 | CS |
52 | -0.0056 | -14.5833333333 | 0.0384 | 0.045 | 0.017 | 160971 | 0.02900441 | CS |
156 | -0.1173 | -78.1479013991 | 0.1501 | 0.259 | 0.01 | 176104 | 0.0668073 | CS |
260 | -0.2072 | -86.3333333333 | 0.24 | 0.36 | 0.01 | 185178 | 0.09463851 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions